Literature DB >> 28542835

Subcutaneous rituximab can be safely administered without pre-medication.

Samuel H Burrows1, Oluwatosin Akinbobuyi1, Simon Rule1, Nicola Crosbie1.   

Abstract

Entities:  

Keywords:  haematological malignancies; immunotherapy; lymphoma; rituximab; subcutaneous

Mesh：

Substances：

Year:  2017        PMID： 28542835     DOI： 10.1111/bjh.14703

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.

Authors:  Pierre Peterlin; Thierry Guillaume; Alice Garnier; Amandine Le Bourgeois; Beatrice Mahé; Viviane Dubruille; Nicolas Blin; Pierre Gallas; Cyrille Touzeau; Thomas Gastinne; Anne Lok; Patrick Thomare; Cecile Chauvin; Steven Le Gouill; Philippe Moreau; Patrice Chevallier
Journal:  Leuk Res Rep       Date:  2018-01-17

Review 2.  Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Authors:  Andrew Davies; Claude Berge; Axel Boehnke; Anjum Dadabhoy; Pieternella Lugtenburg; Simon Rule; Mathias Rummel; Christine McIntyre; Rodney Smith; Xavier Badoux
Journal:  Adv Ther       Date:  2017-10-05       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.